Wall Street brokerages predict that Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) will announce sales of $60,000.00 for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Aurinia Pharmaceuticals’ earnings. The lowest sales estimate is $30,000.00 and the highest is $100,000.00. Aurinia Pharmaceuticals posted sales of $30,000.00 during the same quarter last year, which suggests a positive year-over-year growth rate of 100%. The company is expected to report its next quarterly earnings report on Friday, November 3rd.
On average, analysts expect that Aurinia Pharmaceuticals will report full year sales of $60,000.00 for the current financial year, with estimates ranging from $120,000.00 to $500,000.00. For the next financial year, analysts forecast that the company will report sales of $240,000.00 per share, with estimates ranging from $100,000.00 to $500,000.00. Zacks Investment Research’s sales averages are an average based on a survey of research analysts that that provide coverage for Aurinia Pharmaceuticals.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last announced its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.10. Aurinia Pharmaceuticals had a negative net margin of 16,648.93% and a negative return on equity of 28.61%. The company had revenue of $0.33 million during the quarter, compared to analysts’ expectations of $0.06 million.
A number of equities research analysts have recently issued reports on the stock. Vetr cut shares of Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating and set a $6.64 target price for the company. in a research report on Wednesday, September 6th. Zacks Investment Research raised shares of Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 target price for the company in a research report on Tuesday, August 15th. Cantor Fitzgerald set a $14.00 target price on shares of Aurinia Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 11th. BidaskClub cut shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Finally, HC Wainwright reduced their target price on shares of Aurinia Pharmaceuticals from $12.00 to $10.00 and set a “buy” rating for the company in a research report on Thursday, May 18th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. Aurinia Pharmaceuticals has an average rating of “Buy” and a consensus price target of $9.71.
ILLEGAL ACTIVITY WARNING: “$60,000.00 in Sales Expected for Aurinia Pharmaceuticals Inc (AUPH) This Quarter” was first published by Markets Daily and is owned by of Markets Daily. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.themarketsdaily.com/2017/09/12/60000-00-in-sales-expected-for-aurinia-pharmaceuticals-inc-auph-this-quarter.html.
Shares of Aurinia Pharmaceuticals (NASDAQ AUPH) traded down 5.28% during trading on Tuesday, hitting $6.46. 1,031,500 shares of the stock were exchanged. Aurinia Pharmaceuticals has a 1-year low of $1.97 and a 1-year high of $10.54. The company’s market cap is $539.31 million. The firm’s 50-day moving average is $6.22 and its 200 day moving average is $6.62.
A number of hedge funds have recently bought and sold shares of the stock. AWM Investment Company Inc. raised its stake in Aurinia Pharmaceuticals by 17.5% in the second quarter. AWM Investment Company Inc. now owns 352,500 shares of the biotechnology company’s stock valued at $2,161,000 after purchasing an additional 52,500 shares in the last quarter. Redmile Group LLC raised its stake in Aurinia Pharmaceuticals by 137.0% in the second quarter. Redmile Group LLC now owns 332,310 shares of the biotechnology company’s stock valued at $2,037,000 after purchasing an additional 192,067 shares in the last quarter. Kazazian Asset Management LLC raised its stake in Aurinia Pharmaceuticals by 47.3% in the second quarter. Kazazian Asset Management LLC now owns 66,304 shares of the biotechnology company’s stock valued at $406,000 after purchasing an additional 21,304 shares in the last quarter. Royal Bank of Canada raised its stake in Aurinia Pharmaceuticals by 8.6% in the second quarter. Royal Bank of Canada now owns 16,968 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 1,341 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in Aurinia Pharmaceuticals by 357.3% in the second quarter. Goldman Sachs Group Inc. now owns 876,461 shares of the biotechnology company’s stock valued at $5,373,000 after purchasing an additional 684,816 shares in the last quarter. 27.83% of the stock is owned by institutional investors and hedge funds.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.